18P - Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Multicentric, retrospective and prospective collection of patient data and biomate...

Date 07 May 2015
Event IMPAKT 2015
Session Welcome reception and Poster Walk
Topics Breast Cancer, Metastatic
Translational Research
Presenter Volkmar Müller
Citation Annals of Oncology (2015) 26 (suppl_3): 6-9. 10.1093/annonc/mdv115
Authors V. Müller1, E. Laakmann1, T. Fehm2, V. Möbus3, G. von Minckwitz4, J. Kaiser4, S. Loibl4, I. Witzel1
  • 1Department Of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg - Hamburg/DE
  • 2Department Of Obstetrics And Gynecology, Univesitätsklinikum Düsseldorf, 40225 - Düsseldorf/DE
  • 3Department Of Obstetrics And Gynecology, Klinikum Frankfurt Hoechst, 65929 - Frankfurt am Main/DE
  • 4Medicine And Research, German Breast Group, GBG Forschungs GmbH, 63263 - Neu-Isenburg/DE



Background: The incidence of brain metastases in breast cancer patients is rising and has become a mayor clinical challenge in recent years. So far, limited therapeutic options and insights into the biology of brain metastases exist. Most reports include patients with brain metastases from different tumor entities. Few studies have thus far analyzed exclusively patient data and tumor samples from brain metastases of breast cancer patients. A multicentric registry and biobank should be helpful for analysis of a large number of breast cancer patients with brain metastases. Therefore we initiated the Brain Metastases in Breast Cancer Network Germany (BMBC; GBG79).

Database characteristics: Registration of patient data is allowed retrospectively as well as prospectively. To enable an easy multicentric access, an internet-based database was chosen (“MedCodes” of the German Breast Group). Captured data include incidence, number and localization of brain metastases, histopathologic characteristics, imaging methods applied, outcome, therapy and quality of life measurement. Tissue of brain metastases and primary tumors will be collected for translational research projects. Planned analyses include treatment patterns in Germany, patient outcome, as well as validation of prognostic scoring systems in a multicenter setting and in the context of new targeted therapies. Planned translational research projects include the impact of glycosylation, resistance mechanisms against HER2-targeted therapies, the role of the blood brain barrier, evaluation of markers of radioresistance and specific genomic alterations associated with brain tropism of breast cancer cells. The accrual target is 1000 patients in the database and 400 tissues of brain metastases from participating German centers. The study was opened for documentation in 2014 with 75 participating centers and more than 600 patients started documentation as of January 2015.

Disclosure: All authors have declared no conflicts of interest.